NCT00002540Active, not recruiting
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for prostate cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 76685 (actual)
- First submitted
- 1 Nov 1999
- Start date
- 16 Nov 1993
- Primary completion date
- 21 May 2012
- Lead sponsor
- National Cancer Institute (NCI)
- NCT number
- NCT00002540
What you commit to
- Study type: Interventional
- Participants enrolled: 76685
- From 16 Nov 1993 to the primary completion date, 21 May 2012
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals with previous surgical removal of the entire colon, one lung, or the entire prostate
- Males who have taken Proscar/Propecia/finasteride in the past 6 months
- NOTE: Individuals who are already enrolled in the trial when their physician prescribes finasteride are not prevented from taking this medication. As a result, these participants will continue to be screened and followed just as those participants who are not on finasteride.
- NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO Screening Trial.
Other illness
- Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
- Individuals with known prior cancer of the colon, rectum, lung, prostate
- This includes primary or metastatic PLCO cancers
- Individuals who are participating in another cancer screening or cancer primary prevention trial
Age
- Men who at the time of randomization are less than 55 or greater than or equal to 75 years of age
Other
- Individuals who are unwilling or unable to sign the informed consent form
- Males who have had more than one PSA blood test in the past three years
- Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years
Age in the registry: 55 years to 74 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Institutes of Health Clinical Center Coordinator of this site? Confirm its status | Bethesda | United States | Unknown status |
Related publications
- Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial.BJC Rep · 2025 · PMID 41261199
- Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer.J Nutr · 2014 · PMID 24623848
This page is information, not medical advice. Discuss any trial with your doctor.